Revelation Biosciences Valuation
| REVB Stock | USD 3.06 0.11 3.73% |
At this time, the company appears to be undervalued. Revelation Biosciences holds a recent Real Value of $45.0 per share. The prevailing price of the company is $3.06. Our model determines the value of Revelation Biosciences from analyzing the company fundamentals such as Return On Equity of -2.33, shares outstanding of 4.6 M, and Shares Owned By Institutions of 1.70 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Revelation Biosciences' valuation include:
Price Book 1.5715 | Enterprise Value | Enterprise Value Ebitda (1.02) | Price Sales 2.8821 | Forward PE 0.8875 |
Undervalued
Today
Please note that Revelation Biosciences' price fluctuation is not too volatile at this time. Calculation of the real value of Revelation Biosciences is based on 3 months time horizon. Increasing Revelation Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Revelation Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Revelation Stock. However, Revelation Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.06 | Real 45.0 | Target 170.73 | Hype 3.21 | Naive 2.1 |
The real value of Revelation Stock, also known as its intrinsic value, is the underlying worth of Revelation Biosciences Company, which is reflected in its stock price. It is based on Revelation Biosciences' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Revelation Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Revelation Biosciences helps investors to forecast how Revelation stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Revelation Biosciences more accurately as focusing exclusively on Revelation Biosciences' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Revelation Biosciences' intrinsic value based on its ongoing forecasts of Revelation Biosciences' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Revelation Biosciences' closest peers. If more than one evaluation category is relevant for Revelation Biosciences we suggest using both methods to arrive at a better estimate.
Revelation Biosciences Cash |
|
Revelation Valuation Trend
Comparing Revelation Biosciences' enterprise value against its market capitalization is a good way to estimate the value of Revelation Biosciences uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Revelation Biosciences Total Value Analysis
Revelation Biosciences is at this time anticipated to have valuation of 822.46 K with market capitalization of 13.58 M, debt of 1.91 M, and cash on hands of 3.48 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Revelation Biosciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
822.46 K | 13.58 M | 1.91 M | 3.48 M |
Revelation Biosciences Asset Utilization
One of the ways to look at asset utilization of Revelation is to check how much profit was generated for every dollar of assets it reports. Revelation Biosciences holds a negative application of assets of -0.55 pct., losing $0.005468 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Revelation Biosciences shows how discouraging it operates for each dollar spent on its assets.Revelation Biosciences Ownership Allocation
The market capitalization of Revelation Biosciences is $13.58 Million. Roughly 96.03 pct. of Revelation Biosciences outstanding shares are held by general public with 2.27 % owned by insiders and only 1.7 (%) by third-party entities. On August 6, 2019, Senator Pat Toomey of US Senate acquired $15k to $50k worth of Revelation Biosciences's common stock.Revelation Biosciences Profitability Analysis
Net Loss for the year was (15.04 M) with profit before overhead, payroll, taxes, and interest of 90.91 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Revelation Biosciences' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Revelation Biosciences and how it compares across the competition.
About Revelation Biosciences Valuation
The stock valuation mechanism determines Revelation Biosciences' current worth on a weekly basis. Our valuation model uses a comparative analysis of Revelation Biosciences. We calculate exposure to Revelation Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Revelation Biosciences's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -27.9 K | -26.5 K |
Revelation Biosciences Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 171.5 K | |
| Forward Price Earnings | 0.8875 |
Revelation Biosciences Current Valuation Indicators
Valuation refers to the process of determining the present value of Revelation Biosciences and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Revelation we look at many different elements of the entity such as Revelation's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Revelation Biosciences, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Revelation Biosciences' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Revelation Biosciences' worth.Complementary Tools for Revelation Stock analysis
When running Revelation Biosciences' price analysis, check to measure Revelation Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revelation Biosciences is operating at the current time. Most of Revelation Biosciences' value examination focuses on studying past and present price action to predict the probability of Revelation Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revelation Biosciences' price. Additionally, you may evaluate how the addition of Revelation Biosciences to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| CEOs Directory Screen CEOs from public companies around the world | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |